Published in J Gastroenterol on March 07, 2014
Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein Level Predicts Liver Fibrosis and Prognosis in Primary Biliary Cirrhosis. Am J Gastroenterol (2015) 0.97
Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol (2014) 0.93
Clinicopathological characteristics and diagnostic performance of Wisteria floribunda agglutinin positive Mac-2-binding protein as a preoperative serum marker of liver fibrosis in hepatocellular carcinoma. J Gastroenterol (2015) 0.83
Use of Wisteria Floribunda Agglutinin-Positive Human Mac-2 Binding Protein in Assessing Risk of Hepatocellular Carcinoma Due to Hepatitis B Virus. Medicine (Baltimore) (2016) 0.81
Liver Cirrhosis: Evaluation, Nutritional Status, and Prognosis. Mediators Inflamm (2015) 0.80
Liver fibrosis markers of nonalcoholic steatohepatitis. World J Gastroenterol (2015) 0.78
Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in non-alcoholic fatty liver disease. PLoS One (2017) 0.75
Impact of Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein in Patients with Hepatitis C Virus-Related Compensated Liver Cirrhosis. Int J Mol Sci (2016) 0.75
Prediction of Hepatocellular Carcinoma Development after Hepatitis C Virus Eradication Using Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein. Int J Mol Sci (2016) 0.75
Evaluation of Fucosylated Haptoglobin and Mac-2 Binding Protein as Serum Biomarkers to Estimate Liver Fibrosis in Patients with Chronic Hepatitis C. PLoS One (2016) 0.75
A proposed predictive model for advanced fibrosis in patients with chronic hepatitis B and its validation. Medicine (Baltimore) (2016) 0.75
Serum Mac-2 binding protein glycosylation isomer predicts grade F4 liver fibrosis in patients with biliary atresia. J Gastroenterol (2016) 0.75
Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics (1988) 70.41
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 22.46
An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology (1996) 12.47
Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology (2003) 10.25
Liver biopsy. N Engl J Med (2001) 9.91
Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology (1994) 9.86
Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology (2002) 6.92
Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology (2005) 5.93
Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet (2001) 5.82
Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet (1986) 3.64
Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. J Hepatol (2011) 2.56
Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol (1998) 2.21
A parallel tracking method for acoustic radiation force impulse imaging. IEEE Trans Ultrason Ferroelectr Freq Control (2007) 2.14
Imaging and estimation of tissue elasticity by ultrasound. Ultrasound Q (2007) 1.75
Assessment of graft fibrosis by transient elastography in patients with recurrent hepatitis C after living donor liver transplantation. Transplantation (2008) 1.51
Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res (1996) 1.41
A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep (2013) 1.27
Tumor-associated antigen 90K/Mac-2-binding protein: possible role in colon cancer. J Cell Biochem (2006) 1.09
Prognostic value of a novel circulating serum 90K antigen in breast cancer. Br J Cancer (1994) 1.08
Comparative study concerning the value of acoustic radiation force impulse elastography (ARFI) in comparison with transient elastography (TE) for the assessment of liver fibrosis in patients with chronic hepatitis B and C. Ultrasound Med Biol (2012) 1.05
New method for assessing liver fibrosis based on acoustic radiation force impulse: a special reference to the difference between right and left liver. J Gastroenterol (2011) 1.05
The HCV serum proteome: a search for fibrosis protein markers. J Viral Hepat (2009) 1.04
Mac-2 binding protein is a novel E-selectin ligand expressed by breast cancer cells. PLoS One (2012) 0.99
MR prediction of liver fibrosis using a liver-specific contrast agent: Superparamagnetic iron oxide versus Gd-EOB-DTPA. J Magn Reson Imaging (2012) 0.90
Reconstruction of a robust glycodiagnostic agent supported by multiple lectin-assisted glycan profiling. Proteomics Clin Appl (2013) 0.86
Improvement of long-term outcomes in hepatitis C virus antibody-positive patients with hepatocellular carcinoma after hepatectomy in the modern era. World J Surg (2011) 0.83
Effect of haemolysis and repeated freeze-thawing cycles on wild boar serum antibody testing by ELISA. BMC Res Notes (2011) 0.83
Hepatic aflatoxin B1-DNA adducts and TP53 mutations in patients with hepatocellular carcinoma despite low exposure to aflatoxin B1 in southern Japan. Liver Int (2011) 0.80
Expression and significance of 90K/Mac-2BP in prostate cancer. Exp Ther Med (2012) 0.79
Acoustic radiation force impulse imaging predicts postoperative ascites resulting from curative hepatic resection for hepatocellular carcinoma. Surgery (2012) 0.79
Functional screen for secreted proteins by monoclonal antibody library and identification of Mac-2 Binding protein (Mac-2BP) as a potential therapeutic target and biomarker for lung cancer. Mol Cell Proteomics (2012) 0.76
Temporal changes in the stiffness of the remnant liver and spleen after donor hepatectomy as assessed by acoustic radiation force impulse: A preliminary study. Hepatol Res (2011) 0.76
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 21.56
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 14.16
Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology (2005) 9.39
Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology (2003) 7.35
Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology (2010) 4.58
Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol (2008) 4.55
Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology (2007) 3.08
Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G. Hepatology (2002) 2.85
Comparison of the methods for profiling glycoprotein glycans--HUPO Human Disease Glycomics/Proteome Initiative multi-institutional study. Glycobiology (2007) 2.71
Nonhepatic cell lines HeLa and 293 support efficient replication of the hepatitis C virus genotype 2a subgenomic replicon. J Virol (2005) 2.63
Helicobacter pylori in North and South America before Columbus. FEBS Lett (2002) 2.57
Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem (2007) 2.44
Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. Gastroenterology (2006) 2.33
Genotype 2a hepatitis C virus subgenomic replicon can replicate in HepG2 and IMY-N9 cells. J Biol Chem (2004) 2.32
Colorectal cancer screening with odour material by canine scent detection. Gut (2011) 2.23
Characteristics of printing company workers newly diagnosed with occupational cholangiocarcinoma. J Hepatobiliary Pancreat Sci (2014) 2.22
Smoking status as a prognostic factor in patients with stage I pulmonary adenocarcinoma. Ann Thorac Surg (2006) 2.21
Classifying hepatitis B virus genotypes. Intervirology (2003) 2.20
A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. J Virol (2009) 2.20
Obstructing spontaneous major shunt vessels is mandatory to keep adequate portal inflow in living-donor liver transplantation. Transplantation (2013) 2.14
Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology (2007) 2.09
Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol (2011) 2.07
MicroRNA-10b is overexpressed in pancreatic cancer, promotes its invasiveness, and correlates with a poor prognosis. Surgery (2011) 2.06
What can be revealed by extending the sensitivity of HBsAg detection to below the present limit? J Hepatol (2008) 2.05
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res (2010) 2.05
A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci U S A (2002) 2.02
Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology (2003) 2.02
Bile duct adenoma and von Meyenburg complex-like duct arising in hepatitis and cirrhosis: pathogenesis and histological characteristics. Pathol Int (2014) 2.01
Consumption of n-3 fatty acids and fish reduces risk of hepatocellular carcinoma. Gastroenterology (2012) 2.00
Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol (2009) 2.00
Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Clin Cancer Res (2005) 1.99
Hepatitis C virus core protein, cytochrome P450 2E1, and alcohol produce combined mitochondrial injury and cytotoxicity in hepatoma cells. Gastroenterology (2005) 1.95
Overexpression of hypoxia-inducible factor 1alpha and p53 is a marker for an unfavorable prognosis in gastric cancer. Clin Cancer Res (2006) 1.89
Clinical significance and potential of hepatic microRNA-122 expression in hepatitis C. Liver Int (2010) 1.86
Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol (2012) 1.84
Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene. J Virol (2002) 1.82
Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. Int J Cancer (2011) 1.81
Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol (2010) 1.80
Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets (2008) 1.75
Visualization of galectin-3 oligomerization on the surface of neutrophils and endothelial cells using fluorescence resonance energy transfer. J Biol Chem (2006) 1.73
Total liquid ventilation provides ultra-fast cardioprotective cooling. J Am Coll Cardiol (2007) 1.73
The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. Am J Gastroenterol (2009) 1.72
Physical activity and colorectal cancer: the Fukuoka Colorectal Cancer Study. Cancer Sci (2006) 1.72
A new subtype (subgenotype) Ac (A3) of hepatitis B virus and recombination between genotypes A and E in Cameroon. J Gen Virol (2005) 1.71
Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation (2009) 1.69
Inflammatory myofibroblastic tumor versus IgG4-related sclerosing disease and inflammatory pseudotumor: a comparative clinicopathologic study. Am J Surg Pathol (2009) 1.66
Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure. J Biol Chem (2010) 1.65
Noroviruses distinguish between type 1 and type 2 histo-blood group antigens for binding. J Virol (2008) 1.65
A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes. Hepatology (2006) 1.65
Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci (2007) 1.64
Diabetic microangiopathy in ischemic limb is a disease of disturbance of the platelet-derived growth factor-BB/protein kinase C axis but not of impaired expression of angiogenic factors. Circ Res (2005) 1.64
Risk factors for and management of delayed intraperitoneal hemorrhage after pancreatic and biliary surgery. Am J Surg (2007) 1.64
Strategies for improving the outcomes of small-for-size grafts in adult-to-adult living-donor liver transplantation. J Hepatobiliary Pancreat Surg (2008) 1.64
Donor complications associated with living donor liver transplantation in Japan. Transplantation (2009) 1.60
Association between arterial stiffness and cerebral white matter lesions in community-dwelling elderly subjects. Hypertens Res (2008) 1.60
Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology (2006) 1.60
Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation. Lung Cancer (2011) 1.60
Long-term results of balloon-occluded retrograde transvenous obliteration for gastric variceal bleeding and risky gastric varices: a 10-year experience. J Gastroenterol Hepatol (2008) 1.59
Improved results of a surgical resection for the recurrence of hepatocellular carcinoma after living donor liver transplantation. Ann Surg Oncol (2010) 1.59
Reconstruction of the middle hepatic vein tributaries using the recipient's recanalized umbilical vein in right-lobe living-donor liver transplantation. Surgery (2006) 1.58
Role of expression of focal adhesion kinase in progression of hepatocellular carcinoma. Clin Cancer Res (2004) 1.58
Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer (2006) 1.57
Advances in esophageal cancer surgery in Japan: an analysis of 1000 consecutive patients treated at a single institute. Surgery (2008) 1.57
Development of a prediction model for 10-year risk of hepatocellular carcinoma in middle-aged Japanese: the Japan Public Health Center-based Prospective Study Cohort II. Prev Med (2012) 1.56
Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis. Ann Surg (2013) 1.56
A population-based cohort study for the risk factors of HCC among hepatitis B virus mono-infected subjects in Japan. J Gastroenterol (2010) 1.53
Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system. J Clin Microbiol (2005) 1.53
Geographical and genetic diversity of the human hepatitis B virus. Hepatol Res (2010) 1.53
Virological and clinical implication of core promoter C1752/V1753 and T1764/G1766 mutations in hepatitis B virus genotype D infection in Mongolia. J Gastroenterol Hepatol (2008) 1.53
Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. Int J Cancer (2006) 1.51
Assessment of graft fibrosis by transient elastography in patients with recurrent hepatitis C after living donor liver transplantation. Transplantation (2008) 1.51
Risk factors that increase mortality after living donor liver transplantation. Transplantation (2012) 1.51
A focused microarray approach to functional glycomics: transcriptional regulation of the glycome. Glycobiology (2005) 1.49
Outcomes of living donor liver transplantation for hepatitis C virus-positive recipients in Japan: results of a nationwide survey. Transpl Int (2014) 1.49
Mutations in hepatitis C virus genotype 1b and the sensitivity of interferon-ribavirin therapy after liver transplantation. J Hepatol (2010) 1.48